Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 8/20 | 0.64 |
| ▸ | F2RL3 | Q96RI0 | 7/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945259 | 0.83 | FYN (0.67) | FYNF2RL3TP53MAPTCA12 | |
| SCHEMBL1945185 | 0.83 | FYN (0.58) | FYNF2RL3MAPTMKNK1CA12 | |
| SCHEMBL1945148 | 0.82 | FYN (0.66) | FYNF2RL3MKNK1CA12CA1 | |
| SCHEMBL1945197 | 0.82 | FYN (0.66) | FYNF2RL3TP53CA12CA1 | |
| SCHEMBL1944208 | 0.81 | FYN (0.58) | FYNF2RL3MAPTCA12CA1 | |
| SCHEMBL1944678 | 0.81 | FYN (0.51) | FYNF2RL3TP53MAPT | |
| SCHEMBL18613722 | 0.81 | FYN (0.62) | FYNF2RL3TP53MAPT | |
| SCHEMBL1946089 | 0.80 | FYN (0.68) | FYNF2RL3TP53MAPT | |
| SCHEMBL1945354 | 0.80 | FYN (0.51) | FYNF2RL3TP53MAPTPIK3CG | |
| SCHEMBL1945239 | 0.80 | FYN (0.55) | FYNF2RL3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-2193133-B1 | IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN KINASE INHIBITORS | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-19 | — | — | EP | disclosed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8563550-B2 | Imidazolothiadiazoles for use as protein kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) | 2013-10-22 | — | — | US | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110190289-A1 | Imidazolothiadiazoles for Use as Protein Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-08-04 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190289-A1 | Imidazolothiadiazoles for Use as Protein Kinase Inhibitors | PIM1, PIM3, PIM2 | FYN 383/4885F2RL3 3047/4885TP53 322/4885 |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | FYN 1977/4885F2RL3 1121/4885TP53 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.